Alterations in hepatic glucose metabolism play a key role in the development of the hyperglycemia observed in type 2 diabetes. Because the transcription factor c-Myc induces hepatic glucose uptake and utilization and blocks gluconeogenesis, we examined whether hepatic overexpression of c-myc counteracts the insulin resistance induced by a high-fat diet. After 3 months on this diet, control mice became obese, hyperglycemic, and hyperinsulinemic, indicating that they had developed insulin resistance. In contrast, transgenic mice remained lean and showed improved glucose disposal and normal levels of blood glucose and insulin, indicating that they had developed neither obesity nor insulin resistance. These findings were concomitant with normalization of hepatic glucokinase and pyruvate kinase gene expression and enzyme activity, which led to normalization of intrahepatic glucose-6-phosphate and glycogen content. In the liver of control mice fed a high-fat diet, the expression of genes encoding proteins that control energy metabolism, such as sterol receptor element binding protein 1-c, peroxisome proliferator activated receptor α, and uncoupling protein-2, was altered. In contrast, in the liver of transgenic mice fed a high-fat diet, the expression of these genes was normal. These results suggest that c-myc overexpression counteracted the obesity and insulin resistance induced by a high-fat diet by modulating the expression of genes that regulate hepatic metabolism.
ype 2 diabetes is among the most common metabolic disorders. It is characterized by decreased response of the liver and peripheral tissues to insulin (insulin resistance) and by insufficient compensatory insulin secretion (1) (2) (3) . When the β-cell no longer secretes enough insulin to compensate for the insulin resistance, fasting hyperglycemia and overt diabetes develop (1, 2) . In the Western world, there has been a marked increase in obesity, which is characterized by an alteration of the control of fat deposition and is frequently associated with dyslipidemia, insulin resistance, and type 2 diabetes (4, 5) . Although skeletal muscle and adipose tissue contribute to the development of whole-body insulin resistance, liver dysfunction may also cause hyperglycemia and insulin resistance (2, 3) . An excessive hepatic glucose output is tightly T correlated with fasting hyperglycemia in type 2 diabetes (2) . Furthermore, insulin fails to suppress gluconeogenesis, thus contributing to hyperglycemia (2) . Transgenic rodent models overexpressing phosphoenolpyruvate carboxykinase (PEPCK), a regulatory enzyme of gluconeogenesis, showed increased chronic hepatic glucose production, hyperinsulinemia, hyperglycemia, and insulin resistance (6, 7) . Similarly, mice lacking insulin receptors in the liver display hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance (3) . These models suggest that primary alterations in the rate of hepatic glucose production may induce insulin resistance. Furthermore, liver insulin resistance may result in increased β-cell insulin secretion and decreased hepatic insulin clearance, thus promoting the hyperinsulinemia observed in type 2 diabetes (3, 8) . The liver is also a key tissue for glucose uptake and storage, and may account for disposal of up to one-third after an oral glucose load (1, 9) . Therefore, the defect in hepatic glucose uptake may have a role in the pathogenesis of insulin resistance and type 2 diabetes (10, 11) . Thus, engineering this tissue to uptake glucose might prevent insulin resistance.
Higher glucose uptake and utilization have been shown by increasing glucokinase (GK) gene expression, the main glucose phosphorylating enzyme in the liver (12) (13) (14) (15) (16) . Expression of GK gene is induced by glucose and insulin. Glucose also stimulates transcription of genes for glucose transporters and glycolytic and lipogenic enzymes such as L-type pyruvate kinase (L-PK), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS) and represses the expression of gluconeogenic genes, such as PEPCK (17, 18) . The glucose response involves E-boxes within the glucose/carbohydrate regulatory elements located in the promoter of these genes (19, 20) . cMyc is a basic helix-loop-helix (bLHL)-leucine zipper transcription factor that interacts with E boxes with the sequence CACGTG (21) (22) (23) . We have previously shown that an increase in cMyc protein in the liver of transgenic animals induces hepatic glycolysis, by increasing the expression of genes coding for enzymes that control the glycolytic pathway, such as GK and L-PK, in the absence of cell proliferation and transformation (24) (25) (26) . These changes of liver glucose metabolism reduced blood glucose and insulin concentrations. In addition, after an intraperitoneal glucose tolerance test, transgenic mice showed lower levels of blood glucose than controls, indicating that overexpression of c-Myc increased blood glucose disposal by the liver (24) (25) (26) .
In the present study, transgenic mice overexpressing c-myc were fed a high-fat diet to examine whether an increase in hepatic glucose disposal prevents obesity and insulin resistance. We found that c-myc overexpression normalizes insulinemia, glycemia, and the expression of genes that regulate hepatic metabolism in these mice.
MATERIALS AND METHODS

Treatment of mice
Transgenic mice overexpressing c-myc in the liver under control of the PEPCK promoter were obtained as described previously (24) (25) (26) . Mice were fed ad libitum with a standard diet (Panlab, Barcelona, Spain) and maintained under a light-dark cycle of 12 h (lights on at 8:00 a.m.). For the experimental induction of type 2 diabetes, mice aged 4 months were kept in individual cages and fed a high-fat diet (Harlan Teklad TD 88137, Madison, WI) for up to 3 months. When stated, mice were fasted for 16 h. Animals were anesthetized with isofluorane (between 9 and 11 a.m.) and killed by decapitation, and blood and tissue samples obtained. In the experiments described below, heterozygous transgenic male mice were used. We used littermates as controls. All experimental procedures involving mice were approved by the Ethics and Experimental Animal Committee of the Universitat Autònoma de Barcelona.
RNA analysis
Total RNA was obtained from liver by the guanidine isothiocyanate method (27) , and RNA samples (30 µg) were electrophoresed on a 1% agarose gel containing 2.2 M formaldehyde and then transferred to nylon membranes by capillary blotting. Northern blots were hybridized to the following 32 P-labeled cDNA probes: c-myc, GK, L-PK, GLUT2, PEPCK, β-actin (24-31); SREBP1-c (provided by B. Spiegelman) (32); mouse PPARα (provided by P. Tontonoz) (33); mouse RXRα (provided by P. Chambon); and human UCP2 (34) . These probes were labeled using [α- 32 P]dCTP, following the method of random oligopriming as described by the manufacturer (Roche Molecular Biochemicals, Munich, Germany). Specific activity of the DNA probe thus labeled was ~10 9 cpm/µg DNA. Membranes were placed in contact with Kodak (Rochester, NY) XAR-5 films. The amount of mRNA expressed in individual samples was measured by densitometry and then normalized to the level of β-actin. The mean and standard deviation for at least six samples were calculated to validate the statistical significance of observed changes.
Hormone, enzyme, and metabolite assays
Hepatic GK and L-PK enzyme activities were analyzed in liver samples as described previously (24) (25) (26) . The concentrations of glycogen, glucose 6-phosphate, and lactate were measured in perchloric extracts as indicated previously (24) (25) (26) . The triglyceride content in the liver was measured as indicated elsewhere (35) . Glucose concentration in blood was determined by using a Glucometer Elite (Bayer Diagnostics Europe Ltd., Chapel Lane, Swords, Co. Dublin, Ireland) following the manufacturer's instructions. Serum-free fatty acids were measured by the acylCoA synthase and acyl-CoA oxidase method (Wako Chemicals, Neuss, Germany). Serum triglycerides were determined enzymatically (GPO-PAP, Roche Molecular Biochemicals). Insulin levels in serum were determined by radioimmunoassay (RIA) (CIS Biointernational, Gifsur-Yvette France). Serum parameters, enzyme activities, and metabolite concentrations were expressed as the means ±SE.
Intraperitoneal glucose tolerance test
For glucose tolerance test, control and transgenic mice were fasted overnight (16 h) with free access to water and then given an intraperitoneal injection of glucose (1 g/kg of body weight). Blood samples were obtained from tail vein before the glucose injection and at the indicated time points after the glucose load. Glucose concentration was determined as indicated above.
Statistical analysis
Analysis of statistical differences between data were performed using the Student-NewmannKeuls test. Differences were considered statistically significant at P<0.05.
RESULTS
Transgenic mice overexpressing c-myc were protected from diet-induced obesity.
To determine whether hepatic overexpression of c-myc counteracts insulin resistance, 4-monthold control and transgenic mice were fed a high-fat diet for 3 months. During this period, control (Std-Con) and transgenic (Std-Tg) mice fed a standard diet showed an increase of ~15% in body weight (from 28.6±0.5 g to 32.8±0.8 g and from 26.8±0.5 g to 30.8±0.7 g, respectively) ( Fig. 1) . Control mice fed a high-fat diet (Fat-Con) gained ~40% (from 28.6±0.6 g to 40.1±1.9 g) (Fig. 1) . In contrast, transgenic mice fed this high-fat (Fat-Tg) diet gained ~20% (from 26.8±0.8 g to 31.9±1.0 g) (Fig. 1) . Furthermore, Fat-Con mice showed higher fat accumulation in adipose tissue than transgenic mice, as detected by the increased weight of the epididymal fat pad (FatCon, 2.2±0.4 g, and Fat-Tg, 0.6±0.2 g). Both control and transgenic mice had similar food intake (~4.4±0.3 g standard diet/day and 4.1±0.5 g high-fat diet/day). This indicated that overexpression of c-myc protected mice from diet-induced obesity. Furthermore, overexpression of c-myc did not lead to proliferation or transformation in the liver (data not shown).
Prevention of insulin resistance by overexpression of c-myc in the liver.
Hyperinsulinemia (about threefold increase) and mild hyperglycemia were observed in Fat-Con mice both in fed and in fasted conditions, suggesting that they had developed insulin resistance ( Fig. 2A and 2B ). In contrast, Fat-Tg were normoinsulinemic and normoglycemic in both metabolic conditions ( Fig. 2A and 2B ). In addition, when an intraperitoneal glucose tolerance test was performed in overnight-fasted mice, blood glucose levels in Fat-Tg mice were lower (~30%) than those of Fat-Con and similar to those observed in control mice fed a standard diet (Fig. 3) . The increase in circulating glucose was transient and returned to basal levels by 180 min in FatTg, whereas it remained high in Fat-Con mice.
Furthermore, in both fed and fasted conditions, Fat-Tg mice showed normal concentration of serum triglycerides and free fatty acids (FFA), which were increased in Fat-Con mice (Table 1) . These results suggested that transgenic mice overexpressing c-myc counteracted the development of obesity and insulin resistance noted in control mice after feeding a high-fat diet.
c-myc overexpression induced the expression and activity of key genes involved in the control of hepatic glycolysis
To determine the expression of key genes involved in the regulation of hepatic glycolysis, total RNA was obtained from the liver of control and transgenic mice fed a high-fat diet. When Northern blots were hybridized with a c-myc probe, Fat-Tg mice had similar levels of c-myc mRNA to those observed in transgenic mice fed a standard diet (Fig. 4) (24-26) . In the liver of Fat-Con mice, the expression of GK and L-PK genes decreased (~50%) relative to Std-Con (Fig.  4) . However, Fat-Tg mice expressed high levels of GK (~2.5-fold increase) and L-PK (about threefold) mRNA levels compared with Fat-Con (Fig. 4) . The changes in GK and L-PK mRNA levels were parallel to the enzyme activity (Table 2) . After 3 months on a high-fat diet, a 50% reduction in GK activity was noted in the liver of fed Fat-Con mice compared with fed Std-Con mice, which is consistent with insulin resistance. In addition, these mice showed a reduction in glucokinase activity when fasted, probably resulting from the decrease in insulinemia (Fig. 2) . In contrast, Fat-Tg mice showed a two-and threefold increase in glucokinase activity compared with Fat-Con in fed and fasted conditions, respectively (Table 2) . Moreover, the GK activity noted in the liver of fasted Fat-Tg mice was similar to that of control mice fed a standard diet in both fed and fasted conditions ( Table 2 ). Hexokinase-I activity was the same in the liver of transgenic mice and control mice ( Table 2 ). The reduction of glucokinase activity in Fat-Con mice was associated with a decrease in the intracellular concentration of glucose 6-phosphate (~50%) and in glycogen content (~40%) ( Table 3 ). In contrast, Fat-Tg mice showed similar levels of these metabolites to control mice fed a standard diet both in fed and fasted conditions (Table 3) . Similarly, the normalization of L-PK activity in the liver of Fat-Tg mice was parallel to normalization of their intrahepatic lactate content (Table 3 ). Furthermore, after 3 months on a high-fat diet, the triglyceride content in the liver increased (~2.5 fold) in Fat-Con mice (Table 3) . In contrast, Fat-Tg mice showed a high reduction in the concentration of this metabolite (Table  3) .
Increased hepatic SREBP1-c mRNA levels in transgenic mice overexpressing c-Myc
The sterol regulatory element binding protein-1c (SREBP1-c) induces expression of glycolytic and lipogenic genes in the liver (36, 37) . The overexpression of c-Myc in Std-Tg mice led to an increase (~2.5-fold) in the expression of SREBP-1c compared with Std-Con mice. Similarly, in the liver of Fat-Tg mice, the levels of SREBP1-c also increased (~2.5-fold) compared with FatCon mice (Fig. 4) . Thus, overexpression of c-Myc in the liver of transgenic mice fed a high-fat diet maintained high levels of SREBP1-c expression.
Decreased gene expression of gluconeogenic genes in the liver of Fat-Tg mice
The effects of a high-fat diet on hepatic gluconeogenesis in these animals was also analyzed. The phosphoenolpyruvate carboxykinase (PEPCK) gene expression is induced in insulin resistance and type 2 diabetes (38). Thus, Fat-Con mice showed a marked increase in PEPCK gene expression when compared with Std-Con mice (Fig. 5) . In contrast, transgenic mice fed a highfat diet showed a reduction (about fourfold) in the expression of this gene compared with FatCon mice (Fig. 5) . The decrease in the expression of PEPCK in the liver of Fat-Tg animals was parallel to a decrease in the glucose transporter 2 (GLUT2) mRNA levels (Fig. 5 ), which were also increased in the liver of Fat-Con mice. The mRNA levels of PEPCK and GLUT2 genes in the liver of Fat-Tg mice were similar to those observed in control mice fed a standard diet (Fig.  5) . These findings, together with the increased hepatic glucose uptake and utilization noted in the liver of Fat-Tg mice, may be responsible for the normalization of hepatic glucose production and the reduction of hyperglycemia detected in these transgenic mice.
Down-regulation in the expression of genes involved in energy metabolism in the liver of Fat-Tg mice
Peroxisomal proliferator activated receptor α (PPARα) is present at high levels in the liver, and its activation increases fatty acid oxidation and gluconeogenesis (39, 40) . Parallel to the decrease in PEPCK gene expression, a decrease in the expression of PPARα (about threefold) was observed in the liver of Std-Tg compared with Std-Con mice (Fig. 5) . PPARα gene expression is also induced by obesity and insulin resistance (41) . Similarly, Fat-Con mice showed an increase (about threefold) in the expression of PPARα compared with Std-Con. In contrast, PPARα mRNA levels were reduced (about threefold) in the liver of Fat-Tg mice compared with Fat-Con mice and were similar to those observed in transgenic mice fed a standard diet (Fig. 5) . No changes were detected in the expression of RXRα in the various experimental groups (data not shown) PPARα also regulates uncoupling protein 2 (UCP2) gene expression in the liver (42) . The expression of UCP2 in hepatocytes is markedly induced by obesity (43) . Accordingly, a threefold increase in UCP2 gene expression was noted in the liver of Fat-Con mice compared with Std-Con mice (Fig. 5) . However, the expression of UCP2 was reduced (about threefold) in the liver of Fat-Tg mice compared with Fat-Con mice (Fig. 5) and was similar to that observed in Std-Con mice (Fig. 5) . This was parallel to the normalization of the expression of PPARα gene observed in Fat-Tg mice.
DISCUSSION
Here, we examined the importance of increased hepatic glucose disposal in the prevention of insulin resistance and type 2 diabetes. To this end, we studied the effect of a high-fat diet on control and transgenic mice overexpressing c-myc in the liver. Transgenic mice overexpressing c-myc fed a high-fat diet were lean and showed higher glucose disposal than control mice. In addition, these transgenic mice lessened hyperglycemia and hyperinsulinemia in both fed and fasted conditions, thus indicating that they had developed neither obesity nor insulin resistance. This was achieved most likely through the ability of c-Myc to prevent alterations in the expression and activity of key enzymes involved in the control of hepatic carbohydrate and energy metabolism due to high fat feeding.
GK is a regulatory enzyme of hepatic glucose metabolism and also plays an important role in the maintenance of glucose homeostasis (12) (13) (14) (15) (16) . A marked reduction of GK activity is described in rats fed high-fat diet (44) . Similarly, control mice fed a high-fat diet also showed a marked decrease in GK expression and activity. In contrast, overexpression of c-myc in Fat-Tg mice led to increased GK expression and activity. Similarly, an increase in GK activity in the liver counteracts the development of diet-induced type 2 diabetes in mice (45, 46) . Furthermore, the overexpression of c-myc in the liver of transgenic mice led to normalization in L-PK expression and activity in both fed and fasted conditions. E-boxes have been found in the promoter region of the GK and L-PK genes that might be directly bound and activated by c-Myc (47, 48) . Furthermore, increased expression of SREBP1-c was noted in the liver of transgenic mice overexpressing c-myc fed either a standard or a high-fat diet. This transcription factor controls glycolytic genes such as GK (36, 37) . An E-box motif 5′-CACGTG-3′ has also been located in the SREBP1-c promoter region (49) . Thus, the overexpression of c-myc may up-regulate the SREBP1-c gene expression in transgenic mice, which, in turn, might induce the expression and activity of the enzymes involved in the control of hepatic glucose utilization.
Insulin resistance increases the expression of PEPCK in the liver (38) . Moreover, transgenic rodent models overexpressing PEPCK resulted in increased hepatic glucose production and insulin resistance (6, 7) . Control mice fed a high-fat diet showed a marked increase in PEPCK mRNA levels. However, decreased expression of PEPCK was noted in the liver of Fat-Tg mice overexpressing c-myc, which may have contributed to the normalization of glycemia in these mice. An E-box motif that could be bound by c-Myc has recently been described in the PEPCK promoter (50) . Thus, c-Myc might directly repress PEPCK gene transcription. In addition, SREBP-1c mimics the negative effect of insulin on PEPCK gene transcription (51) . Therefore, the increase in the expression of SREBP-1c detected in the liver of Fat-Tg mice may also be compatible with down-regulation of PEPCK expression in these transgenic mice.
PPARα is also involved in both activation of hepatic gluconeogenesis and mitochondrial β-oxidation. Its expression is down-regulated by insulin and up-regulated by obesity and insulin resistance (39) (40) (41) . In addition, obesity and insulin resistance induce the overaccumulation of intrahepatic triglycerides (52) . After 3 months on a high-fat diet, control mice showed increased levels of PPARα and elevated triglyceride content in the liver. However, the expression of PPARα was not increased in the liver of transgenic mice overexpressing c-myc. This was consistent with reduced intrahepatic triglyceride content in these mice. Similarly, PPARα null mice show greater suppression of endogenous hepatic glucose production and its deficiency led to protection from insulin resistance induced by a high-fat diet (53) . Recently, a down-regulatory element with a putative c-Myc E-box consensus sequence has been described in the PPARα gene (54) . This fact suggests that c-Myc might directly repress PPARα gene expression, which in turn may lead to reduced expression of the PEPCK gene.
PPARα regulates gene transcription through specific PPAR response elements (PPREs) located in the promoter region of target genes (39, 40) . PPREs have also been identified in the promoter of the GLUT2 gene (55) . The induction in PPARα observed in Fat-Con mice was parallel to an increase in GLUT2 mRNA. Consistent with this, GLUT2 gene expression is up-regulated in obesity (56, 57) , and this fact is correlated with an increased glucose output from the liver (56). However, because glucose flux through this transporter is dependent on the intra-and extrahepatic glucose concentration, the normalization of glycemia is probably due to lower PEPCK expression in the liver of Fat-Tg compared with Fat-Con mice.
The mitochondrial UCP2 is involved in the control of thermogenesis and is expressed, among other tissues, in the liver (34, 58) . Because UCP2 may play a role in energy dissipation, an increase in UCP2 expression may be beneficial in reducing obesity. However, it has also been described that UCP2 expression in liver increases during obesity, as a possible adaptation of the liver to an excess of substrate supply (43) . In our study, the increase in UCP2 in Fat-Con may result from obesity. The finding that Fat-Tg did not show an increase in UCP2 expression may be due to the lack of body weight gain.
Furthermore, PPARα activation in mice induces liver UCP2 gene expression (42) . Thus, after 3 months on a high-fat diet, control mice showed a marked increase in the expression of UCP2 in the liver. In contrast, the hepatic expression of UCP2 remained normal in transgenic mice, and this was similar to the expression of the PPARα gene.
In summary, our results suggest that overexpression of c-myc in the liver counteracts the development of obesity and insulin resistance induced by a high-fat diet by restoring the expression and activity of key enzymes involved in the control of hepatic metabolism. It is possible that c-Myc directly, through transcriptional activation/repression, controls a network that regulates energy turnover (PPARα and UCP2 genes) and glucose metabolism (GK, PEPCK, and SREBP1-c genes). Furthermore, our results indicate that hepatic overexpression of c-myc is enough for normalization of insulin resistance, indicating the key role of the liver in the control of whole-body glucose homeostasis. This transgenic model also suggests that engineering the liver both to increase glucose uptake and utilization and to block glucose production may be a useful approach to prevent obesity and insulin resistance. mice fed a standard diet and control (Fat-Con) and transgenic (Fat-Tg) mice after 2.5 months on a high-fat diet were given an intraperitoneal injection of glucose (1 mg/g of body weight). Blood samples were taken at the times indicated from the tail vein of the same animal. Glucose was measured as indicated in Materials and Methods. Results are means ±SE of 12 animals for each group.
∫ Significantly different from the corresponding value in control mice on a high-fat diet (Fat-Tg vs. Fat-Con; *P<0.05).
† Significantly different from the corresponding value in same genotype animals on different diet (StdCon vs. Fat-Con; *P<0.05). mRNA levels for different genes were analyzed by Northern blot analysis. Total RNA was obtained from the liver of control (Std-Con) and transgenic (Std-Tg) mice fed a standard diet (Std-diet) and in control (Fat-Con) and transgenic (FatTg) mice after 3 months on a high-fat diet (HF-diet) and analyzed as described in Materials and Methods. Right panel: The signals obtained were quantified by densitometric analysis, normalized for loading inequalities with β-actin and expressed as a percentage of control mice fed a standard diet (100%). Results are the mean ±SE of at least six mice in each experimental group.
† Significantly different from the corresponding value in control mice on the same diet (Std-Tg vs. StdCon and Fat-Tg vs. Fat-Con; *P<0.05; **P<0.01).
∫ Significantly different from the corresponding value in same genotype animals on different diet (Std-Con vs. Fat-Con; *P<0.05). Left panel: A representative Northern blot hybridized with cmyc, GK, L-PK, and SREBP1-c, and with β-actin-specific probes, is shown. analyzed by Northern blot analysis. Total RNA was obtained from the liver of control (Std-Con) and transgenic (Std-Tg) mice fed a standard diet (Std-diet) and in control (Fat-Con) and transgenic (Fat-Tg) mice after 3 months on a high-fat diet (HF-diet) and analyzed as described in Mataerials and Methods. Right panel: The signals obtained were quantified by densitometric analysis, normalized for loading inequalities with β-actin, and expressed as a percentage of control mice fed a standard diet (100%). Results are the mean ±SE of at least six mice in each experimental group.
† Significantly different from the corresponding value in control mice on a high-fat diet (Std-Tg vs. Std-Con and Fat-Tg vs. Fat-Con; *P<0.05; **P<0.01).
∫ Significantly different from the corresponding value in same genotype animals on a different diet (Std-Con vs. Fat-Con; **P<0.01). Left panel: A representative Northern blot hybridized with PEPCK, GLUT2, PPARα, and UCP2, and with β-actin-specific probes, is presented.
